An observational study of the risk of neonatal macrosomia, and early gestational diabetes associated with selected candidate genes for type 2 diabetes mellitus polymorphisms in women with gestational diabetes mellitus by Zawiejska, Agnieszka et al.
705
ORIGINAL PAPER /  OBSTE TRICS
Ginekologia Polska
2018, vol. 89, no. 12, 705–710
Copyright © 2018 Via Medica
ISSN 0017–0011
DOI: 10.5603/GP.a2018.0119
Corresponding author:
Agnieszka Zawiejska  
Department of Reproduction, Karol Marcinkowski University of Medical Sciences, 33 Polna St., 60–535 Poznan, Poland
e-mail: azawiejska@ump.edu.pl
An observational study of the risk of neonatal 
macrosomia, and early gestational diabetes associated 
with selected candidate genes for type 2 diabetes 
mellitus polymorphisms in women with gestational 
diabetes mellitus
Agnieszka Zawiejska1, Ewa Wender-Ozegowska1, Anna Bogacz2, 
Rafal Iciek3, Przemyslaw Mikolajczak4, Jacek Brazert3
1Department of Reproduction, Karol Marcinkowski University of Medical Sciences, Poznan, Poland 
2Department of Stem Cells and Regenerative Medicine, Institute of Natural Fibers and Medicinal Plants, Poznan, Poland 
3Department of Obstetrics and Women’s Diseases, Karol Marcinkowski University of Medical Sciences, Poznan, Poland  
4Chair of Pharmacology, Karol Marcinkowski University of Medical Sciences, Poznan, Poland 
ABSTRACT
Objectives: 1) to analyse the prevalence of selected candidate genes for type 2 diabetes mellitus polymorphisms (IRS1 G972R; 
ENPP1 K121Q; ADRB3 W64R) among women with gestational diabetes; and 2) to investigate any association between vari-
ants of these genes and risk of neonatal macrosomia. 
Material and methods: We conducted a prospective observational study of a group of women (N = 140) in singleton preg-
nancies who delivered at term. Characteristics of the study group at enrolment: age: 32.0 ± 4.9 years; GA: 26.6 ± 7.5 weeks; 
HbA1c: 5.6 ± 0.6%; fasting blood glucose: 102.3 ± 16.3 mg/dL; insulin treatment (G2DM): 65.7%; chronic hypertension: 
11.4%; gestational hypertension: 17.9%; preeclampsia: 1.4%; birth weight: 3590 ± 540 g; birth weight ≥ 4000 g (macrosomia): 
18.6%; caesarean section: 44.3%; and female newborns: 57.1%.
Results: The maternal metabolic characteristics at the time of booking did not differ between polymorphisms. Macrosomia 
was insignificantly more frequent in females (22.5%) than in males (13.3%) (p = 0.193). Only maternal height and body 
weight at the time of booking significantly predicted birth weight (R = 0.27, p = 0.007; R = 0.25, p = 0.005, respectively). 
IRS1 G972R GR and ENPP1 K121Q KQ polymorphisms were associated with an insignificantly increased risk for macrosomia. 
Carriers of the heterozygotic variant of the IRS 1 gene were significantly more likely to be diagnosed with GDM/DiP in the 
first trimester: OR 5.2, 95% CI: 1.4; 19.2; p = 0.014.
Conclusions: 1) having similar metabolic characteristics, carriers of specific variants of T2DM candidate genes might be at 
increased risk of delivery of macrosomic newborns; 2) any association between genetic variants and macrosomia in this 
population might be gender-specific; and 3) allelic variation in the IRS1 gene is associated with early GDM/DiP.
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INTRODUCTION
Hyperglycemia detected in pregnancy known as ges-
tational diabetes mellitus (GDM) or diabetes diagnosed in 
pregnancy (DiP), is a common complication of pregnancy 
and is associated with increased fetomaternal risk. Associa-
tions between GDM/DiP and short-term adverse perinatal 
outcomes are well described, and excessive fetal growth 
and macrosomia are particularly characteristic of this ma-
ternal disease [1, 2]. According to recent studies focusing on 
long-term follow-up of patients, GDM/DiP is a strong predic-
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tor for type 2 diabetes in women and has been shown to be 
related to an increased risk of non-communicable disorders 
in their offspring [3–5]. 
Type 2 diabetes mellitus (T2DM) is a complex disorder 
in which multigenic predisposition is strongly shaped by 
epigenetic (environmental) factors. Although recent stud-
ies identify a growing number of genes that can be linked 
to increased T2DM susceptibility, the risk continues to be 
significantly influenced by lifestyle interventions. Therefore, 
the clinical relevance of information obtained from genomic 
investigations is still a matter of controversies. 
As GDM/DiP and type 2 diabetes share clinical pheno-
types, namely several pathomechanisms and risk factors, 
both diseases are now considered to be a clinical manifes-
tation of an ongoing process that accumulates over time in 
a woman’s lifetime. Therefore, several studies have investi-
gated for a possible common genetic background in these 
disorders. Observational data from different cohorts world-
wide, confirm there is a significantly increased prevalence 
of the T2DM risk variants of particular candidate genes in 
women with gestational diabetes [6]. However, this asso-
ciation was only confirmed in the case of some candidate 
genes. Moreover, studies of small cohorts often produce 
conflicting results, and all conclusions are relevant for specific 
populations. Also, data from GDM cohorts refer to only a few 
T2DM candidate genes out of a large number of identified 
risk variants. Additionaly, for some associations, maternal 
BMI was found to be a possible or actual determining factor 
explaining the relationships found by researchers [7–10]. 
Importantly, the majority of available data only focuses 
on links between the genetic profile and the prevalence of 
GDM in particular cohorts. There have only beeen a small 
number of studies that have looked into a possible rela-
tionship between the variants and the degree of maternal 
hyperglycemia. None of the research currently available 
has addressed fetomaternal outcomes, abnormal growth 
trajectories, or maternal metabolic profiles in GDM pregnan-
cies. Therefore, although it may be useful from the point of 
view of the populations, the available research evidence 
is not helpful for perinatal risk assessment and profiling. 
The aim of our study was to analyse the prevalence 
of particular polymorphisms of selected candidate genes 
for type 2 diabetes mellitus (IRS1 G972R; ENPP1 K121Q; 
ADRB3 W64R) in a cohort of Polish women with gestational 
diabetes and to investigate any associations between vari-
ants of these genes and birth weights in the cohort. 
We hypothesised that being a carrier of a specific variant 
of the candidate gene for type 2 diabetes is associated with 
an altered risk for excessive fetal growth and neonatal mac-
rosomia. We also hypothesised that this association might 
show a sexually dimorphic pattern, that is, differ between 
female and male neonates. 
MATERIAL AND METHODS
We designed a prospective observational trial to an-
swer our research question. All those patients in singleton 
pregnancy who were referred to our tertiary-level unit of 
antenatal care for further treatment of GDM/DiP were con-
sidered eligible for our study. Finally, 199 women agreed 
to participate in the study and each gave their informed 
consent. Our protocol was reviewed and approved by the 
Bioethical Committee at the University of Medical Sciences 
in Poznan. The research project received funding from the 
Polish Ministry of Science (grant No: NN407 536538).
We selected the data of N = 140 women who delivered 
at term (gestational age of 37 or more gestational weeks) for 
the analysis so as to investigate any association between the 
genes we studied and birth weights. From our cohort, we 
collected data on maternal anthropometrics, and lipid and 
glycemic profiles at booking. We also performed an ultrasound 
examination of the fetal growth and body composition. Then, 
patients had their blood taken, which was processed and 
stored for further assaying. After delivery, we collected data on 
birth weight, delivery mode, and adverse maternal and neo-
natal outcomes. Macrosomia was defined as a birth weight of 
4000g or more. We sub-divided our study population accord-
ing to all the polymorphisms studied: IRS1, ADRB3 and ENPP1.
All biochemical tests were performed in the accred-
ited laboratory of the academic hospital, which holds ISO 
9000 quality management certification. 
Genomic DNA was extracted from venous blood samples 
using the QIAamp Blood Kit (Qiagen GmbH, Hilden, Germany) 
according to the manufacturer’s protocol. Analysis of the 
IRS1 G972R, ENPP1 K121Q and ADRB3 W64R polymorphisms 
was performed using the PCR-RFLP method. The primers for 
ADRB3 and ENPP1 used in the PCR, the length of amplified 
products and the conditions of the PCR were applied as pre-
viously described [11, 12]. Primer sequences for the G972R 
polymorphism of the ISR1 gene were as follows: forward 5’- 
GTG ATC AGT CTG GCT ACT TGT -3’, reverse 5’- TGC CTG TTC 
GCA TGT CAG CAT AGC -3’ (348bp). The PCR were performed 
in a thermocycler (PTC-200, MJ Research, USA). PCR products 
were digested with the appropriate restriction enzymes, such 
as SmaI (Fermentas, Lithuania) for ISR1, AvaII (Fermentas, 
Lithuania) for ENPP1 and MvaI (Fermentas, Lithuania) for 
ADRB3. The lengths of fragments of the polymorphisms we 
studied were as follows: IRS1 G972R GG (203 bp, 117 bp, 
28 bp), GR (231 bp, 203 bp, 117 bp, 28 pz), RR (231 bp, 117 bp), 
ENPP1 K121Q KK (238 bp), KQ (238 bp, 148 bp, 90 bp), QQ 
(148 bp, 90 bp) and ADRB3 W64R WW (99 bp, 62 bp), WR 
(161 bp, 99 bp, 62 bp), RR (161 bp). PCR-RFLP products were 
separated using electrophoresis in 3% agarose gel with eth-
idium bromide and they were visualised under UV light.
Statistical analysis was performed using SPSS 14.0.2PL 
for Windows (IBM®, Armonk, USA). We tested the normality 
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of our data using the Kolmogorov-Smirnov test, and then 
we used appropriate parametric or nonparametric tests to 
ascertain the differences between the parameters in each 
of the subgroups. Odds ratios and 95% confidence intervals 
were calculated for proportions of fetal end-points. Multiple 
logistic regression and ROC analyses were performed to 
identify predictors for neonatal macrosomia in the group. 
Variables were presented as means ± standard deviation or 
medians (interquartile range). P < 0.05 was considered as 
statistically significant, with a Bonferroni correction used 
for multiple group testing. 
RESULTS
The characteristics of our study group are summarised 
in Table 1. Our participants were recruited from patients 
who had been referred to our clinic by local units for fur-
ther antenatal care — this explains the high proportions 
of women with early GDM, on insulin therapy, or who had 
been diagnosed with chronic or gestational hypertension.
The initial metabolic profiles of our patients and the final 
fetomaternal outcomes did not differ with any statistical 
significance between carriers of the studied gene variants, 
except for the statistically significant difference in the gesta-
tional age at enrolment between the IRS1 G972R GG and GR 
subgroups (27.5 ± 7.0 vs 21.1 ± 9.6; p = 0.014). Heterozygotes 
were significantly more likely to be diagnosed with GDM/DiP 
in the first trimester: OR 5.2, 95% CI: 1.4; 19.2; p = 0.014. 
The gestational weight gain and prevalence of mater-
nal obesity were similar when the carriers of the genetic 
variants we investigated were compared. For many patients, 
pre-pregnancy body weight data was either not available or 
was self-reported, and therefore of limited accuracy. How-
ever, the pre-pregnancy data we did have, and the patients’ 
body weight at enrolment, that was measured in our depart-
ment, clearly indicated a population with excessive body 
weight prior to pregnancy.
Maternal anthropometric and metabolic parameters 
did not differ significantly between the groups of women 
who delivered normal-weight newborns compared with 
macrosomic newborns (Tab. 2).
Macrosomia was insignificantly more frequent in fe-
males (22.5%) compared with males (13.3%) OR 1.9, 95% 
CI: 0.8, 4.7; p = 0.193. In our study group, only the maternal 
heights and body weights at the time of booking were signif-
icant in predicting birth weights (R = 0.27, p = 0.007; R = 0.25, 
p = 0.005, respectively). We found, in the whole cohort, and 
Table 1. Characteristics of the study group
Age [years] 32.0 ± 4.9
Gestational age at diagnosis [weeks] 24.3 ± 9.8
Gestational age at booking [weeks] 26.6 ± 7.5
HbA1c at booking [%] 5.6 ± 0.6
Fasting blood glucose at booking [mg/dL] 102.3 ± 16.3
Maternal height [cm] 167.0 ± 6.5
Maternal prepregnancy body weight [kg] 91.2 ± 15.0
Maternal weight at booking [kg] 92.5 ± 20.4 
Maternal prepregnancy BMI [kg/m2] 32.8 ± 5.6
Gestational weight gain [kg]
data available for N = 42 patients 6.8 ± 7.1
Maternal prepregnancy obesity [%] 
data available for N = 53 patients 65.4
Chronic hypertension [%] 13.6
Gestational hypertension [%] 17.9
Preeclampsia [%] 1.4
Insulin therapy [%] 65.7
HbA1c > 6.5% at booking [%] 6.3
GDM diagnosed in the first trimester [%] 33.3
GA at delivery [weeks] 39 ± 1
Birth weight [g] 3592 ± 540
Females/males [%] 57/43
Birth weight > 4000 g [%] 18.6
Birth weight > 4000 g in female neonates/male 
neonates [%] 22.5/13.3
Table 2. Metabolic and anthropometric characteristics of participants 
who delivered normal-weight vs macrosomic newborns
Maternal parameter
Normal-
weight 
newborns
N = 114
Macrosomic 
newborns 
(birth weight 
> 4000 g)
N = 26
p
Maternal age [years] 31.9 ± 5.0 32.2 ± 4.4 0.865
Gestational age at diagnosis 
[weeks] 19.7 ± 8.9 24.7 ± 7.7 0.218
Gestational age at booking 
[weeks] 26.4 ± 7.5 27.9 ± 7.6 0.480
HbA1c at booking [%] 5.6 ± 0.6 5.5 ± 0.4 0.902
Fasting blood glucose at 
booking [mg/dL] 102.2 ± 16.5 102.5 ± 16.1 0.913
Maternal height [cm] 166 ± 7 169 ± 6 0.058
Maternal prepregnancy body 
weight [kg] 90.6 ± 14.6 93.1 ± 17.0 0.656
Maternal weight at booking [kg] 91.9 ± 20.0 101.0 ± 21.9 0.058
Maternal prepregnancy BMI 
[kg/m2] 33.1 ± 5.4 32.0 ± 6.4 0.380
Gestational weight gain [kg] 5.9 ± 6.8 10.8 ± 7.1 0.055
Gestational hypertension/ 
preeclampsia [%] 15.9 28.0 0.161
Chronic hypertension [%] 13.6 16.0 0.754
Insulin therapy [%] 67.5 53.8 0.385
HbA1c > 6.5% at booking [%] 7.7 0 0.347
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in the females analysed separately, that IRS1 G972R GR 
and ENPP1 K121Q KQ polymorphisms were associated with 
an insignificantly increased risk for macrosomia (respec-
tively: 17.5% vs 11.5% for the GR polymorphism, p = 0.568; 
and 25.0% vs 16.3% for the KQ polymorphism, p = 0.319). 
No significant relationship was found in our cohort between 
birth weight and allelic variability in the ADRB3 gene.
There was no significant association between birth 
weights and the distribution of the genetic variants we 
studied; however, women who delivered newborns weigh-
ing more than 3620g were more likely to be carriers of the 
ENPP1 K121Q KQ variant (Fig. 1A), and this trend was even 
stronger in the sub-group who gave birth to girls (Fig 1A). 
Patients who gave birth to newborns weighing more 
than 3560 g were more likely to be carriers of the IRS1 G972R 
GR variant (Fig 1B). This association, although weaker, was 
also confirmed in a separate analysis of the mothers of girls 
(Fig 1B). For both genes, we found no threshold linking 
birthweight to a likelihood of being a carrier of the specific 
gene variant in those women who gave birth to boys. 
The prevalence of specific polymorphisms for the whole 
cohort are presented in Table 3. We did not note any as-
sociation between the variants of the genes we studied, 
and neonatal sex. 
DISCUSSION
There is a growing prevalence of gestational diabetes 
mellitus in the general population of pregnant women. This 
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AUC  
(area under curve )
Cutoff 
value Sensitivity Specificity p 
Whole cohort
0.57 
95% CI: 0.55; 0.69 > 3620 g 61.1% 56.7% 0.234
LR for the cutoff value : 1.4 (1.0; 2.0)
Female neonates
0.6 
95% CI: 0.49; 0.71 > 3640 g 66.7% 61.0% 0.184
LR for the cutoff value: 1.7 (1.1; 2.7)
Figure 1A. Birth weight as an indicator of maternal ENPP1K121Q KQ 
polymorphism
AUC 
(area under curve)
Cutoff 
value Sensitivity Specificity p 
Whole cohort
0.55 
95% CI: 0.47; 0.6 > 3560 g 69.6% 50.4% 0.376
LR for the cutoff value: 1.4 (1.0; 1.9)
Female neonates
0.52 
95% CI: 0.41; 0.64 > 3470 g 85.7% 42.4% 0.748
LR for the cutoff value: 1.5 (1.1; 2.0)
Figure 1B. Birth weight as an indicator of maternal IRS1 G972 GR 
polymorphism
Table 3. Prevalence of variants in the study population
ADRB
RR 3.6% WR 11.4% WW 85.0%
ENPP1
KQ 25.7% KK 74.3%
IRS-1
GR 16.4% GG 83.6%
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disease is now identified as one of the main health burdens 
behind increased maternal and neonatal morbidity, from the 
perspectives of both the short-term and long-term implica-
tions. Therefore, both international and local organisations 
are calling for more studies on the risk factors, effective pre-
vention modes and mechanisms of maternofetal intergenera-
tional transmission of non-communicable disorders [13, 14]. 
In our cohort, we linked some maternal and neona-
tal traits to genetic variations of well-described candidate 
genes for T2DM. Our results add to a new area of research 
because most available data concerns allelic variations of 
the candidate genes and their associations with the risk of 
gestational diabetes itself. Only one report has described 
an assocation between genetic variations and how severe 
the hyperglycemia was, and whether the women were re-
sponding to the therapy, or [15].
In our study group, we found that a slightly increased 
risk of excessive birth weight was associated with the variant 
of the insulin receptor substrate-1 gene. A protein encoded 
by this gene is involved in insulin signalling in target tissues, 
and some studies, including one Turkish study, have found 
an association between its genetic variation and a more 
severe GDM phenotype; that is, they found higher insulin 
levels and higher fasting glucose [16]. In our cohort, we 
did not confirm these differences. In comparison, the Turk-
ish data were collected from a smaller group of patients 
diagnosed with a 100 g OGTT. Moreover, our participants 
were recruited from a population that had been referred 
to an academic unit for further care due to the ineffective 
initial treatment they had received or because of other 
co-morbidities. Therefore, our cohort might have been bi-
ased towards more severe phenotypes. Nevertheless, even 
if our study subgroups did not differ in terms of maternal 
characteristics, our observation of an association between 
increased birth weight and genetic variants of the IRS-1 gene 
remains in line with other available evidence on the regu-
lating role of IRS-1 in determining insulin response [17]. 
Contemporary data on perinatal outcomes in GDM popula-
tions consider birth weight as a result of complex maternal 
metabolic disarrangements that are strongly mediated by 
maternal insulin resistance. In our study population, which 
was sub-divided by IRS-1 polymorphisms, we also noticed 
similar proportions of other surrogate markers of severe 
insulin resistance in pregnancy, such as pre-pregnancy obe-
sity, excessive body weight gain, or gestational hyperten-
sion. Therefore, our findings might suggest that specific 
genetic variations in the IRS-1 gene could be associated with 
accelerated fetal growth, even if metabolic changes that 
are specific to late pregnancy mask any differences in the 
background insulin resistance caused by allelic mutations 
of this gene. Alternatively, certain specific polymorphisms 
of the IRS-1 gene might be associated with elevated insu-
lin resistance in early pregnancy that triggers accelerated 
fetal growth – undetected before the third trimester of 
gestation – prior to the affected individual presenting with 
gestational dysglycemia. The placenta is now recognised 
as a key-player by autonomously regulating fetal access 
to maternal nutrients. Hence, we could hypothesise that 
the maternal metabolic phenotype produced by genetic 
variations in the IRS-1 could be dysregulating the placental 
function from early in the pregnancy.
One important aspect of our findings was that we con-
firmed an association between gestational dysglycemia 
diagnosed in early pregnancy and specific allelic variations 
of the IRS-1 gene. Our observation also supports hypoth-
eses on the early pregnancy origins of fetal overgrowth, as 
women with these polymorphisms entered their pregnan-
cies with a more severe insulin resistance and were more 
likely to give birth to large newborns. We also observed 
an association between at least one gene, among numer-
ous candidate genes, for T2DM and maternal perinatal 
complications, in that we found a strong relation between 
variations in the IRS-1 gene and hyperglycemia diagnosed 
in early pregnancy. The group of women diagnosed with 
hyperglycemia early in their pregnancy presents a particu-
lar challenge to antenatal care providers due to a lack of 
uniform recommendations for GDM/DiP screening in early 
pregnancy. Accumulating data from clinical observations 
suggests an increased risk for fetomaternal complications 
when compared with results for GDM/DiP diagnosed at 
a standard gestational age. Also, this early-diagnosed popu-
lation of pregnant women seems more likely to develop 
cardiometabolic complications in later life. Notably, our 
data confirmed that genetic factors can contribute to the 
increased risk of gestational and post-partum complications, 
and this would make lifestyle and behavioural interventions 
less effective.
As with the findings for the IRS-1, the ENPP-1 gene is 
critical for insulin function. A class II transmembrane gly-
coprotein product encoded by ENPP-1 is overexpressed 
in many target tissues for insulin in individuals at risk of 
metabolic syndrome, insulin resistance and future obesity. 
ENPP-1 polymorphisms are also associated with diabetic 
vascular complications [18, 19]. Also, our study confirmed 
a link between this gene and larger birth weights and specif-
ic genetic variations. Moreover, this ENPP-1 association was 
more pronounced in the sub-group of female newborns.
For both the genes that are crucial for insulin action, 
we noted a trend towards a stronger association between 
specific polymorphisms and birth weights for female new-
borns. The aggregated body of evidence points towards 
sex-associated differences in the risk and prognosis of type 
2 diabetes mellitus [20]. Moreover, common metabolic risk 
factors for type 2 diabetes in the female sex are associated 
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with a less favourable prognosis, and women need specifi-
cally tailored interventions to address the specific risks [21]. 
Our data remain in line with these published findings, as 
we traced these gender-related differences back to mater-
nofetal interactions. One might conclude from our findings 
that maternal insulin resistance has a more remarkable 
impact on fetal development if the pregnant woman has 
a daughter. Our study also confirmed the early onset of 
metabolic impairment that is likely to result in increased 
whole-life morbidity in affected women, thus increasing 
their reproductive health risks and reducing their life ex-
pectancy. Moreover, our observations also add to an exist-
ing body of evidence on the matrilineal intergenerational 
transmission of noncommunicable disorders. Our data also 
confirm how important it is to develop effective interven-
tions to prevent increased perinatal risks associated with 
the maternal metabolic profile. Notably, such interventions 
should optimally predate pregnancy — recent data points 
to the postpartum, or interpregnancy period, as a promis-
ing educational window to improve fetomaternal safety in 
future gestations. Unfortunately, our results also indicate 
that environmental interventions in populations that are 
genetically predisposed to diabesity need to be carefully 
designed, and that such interventions probably should take 
account of the genetic profile of the targeted population, 
even if genetic susceptibility accounts only for a small pro-
portion of the risk [22].
CONCLUSIONS
Conclusions: 1/ having similar metabolic characteristics, 
carriers of specific variants of T2DM candidate genes might 
be at increased risk for a delivery of macrosomic newborns; 
2/ associations between genetic variants and macrosomia 
in carriers of specific variants of T2DM candidate genes may 
be gender-specific; 3/ allelic variation in the IRS1 gene is 
associated with early GDM/DiP.
Acknowledgments
This research program was funded from a National Science 
Centre Poland, grant No NN407536538.
REFERENCES
1. Weinert LS, Metzger BE, Gabbe SG, et al. International Association of 
Diabetes and Pregnancy Study Groups Consensus Panel. International 
association of diabetes and pregnancy study groups recommendations 
on the diagnosis and classification of hyperglycemia in pregnancy. 
Diabetes Care. 2010; 33(3): 676–682, doi: 10.2337/dc09-1848, indexed 
in Pubmed: 20190296.
2. Coustan DR, Lowe LP, Metzger BE, et al. The HAPO Study: Paving the 
Way For New Diagnostic Criteria For GDM. Am J Obstet Gynecol . 2010; 
202(6): 654–656.
3. Ben-Haroush A, Yogev Y, Hod M. Epidemiology of gestational diabetes 
mellitus and its association with Type 2 diabetes. Diabet Med. 2004; 
21(2): 103–113, indexed in Pubmed: 14984444.
4. Carr DB, Utzschneider KM, Hull RL, et al. Gestational diabetes mellitus 
increases the risk of cardiovascular disease in women with a family 
history of type 2 diabetes. Diabetes Care. 2006; 29(9): 2078–2083, doi: 
10.2337/dc05-2482, indexed in Pubmed: 16936156.
5. Brewster S, Zinman B, Retnakaran R, et al. Cardiometabolic consequences 
of gestational dysglycemia. J Am Coll Cardiol. 2013; 62(8): 677–684, doi: 
10.1016/j.jacc.2013.01.080, indexed in Pubmed: 23524050.
6. Zhang C, Bao W, Rong Y, et al. Genetic variants and the risk of gestational 
diabetes mellitus: a systematic review. Hum Reprod Update. 2013; 19(4): 
376–390, doi: 10.1093/humupd/dmt013, indexed in Pubmed: 23690305.
7. Ekelund M, Shaat N, Almgren P, et al. Genetic prediction of postpartum 
diabetes in women with gestational diabetes mellitus. Diabetes Res Clin 
Pract. 2012; 97(3): 394–398, doi: 10.1016/j.diabres.2012.04.020, indexed 
in Pubmed: 22591707.
8. Tarquini F, Picchiassi E, Centra M, et al. Body mass index associated 
to rs2021966 ENPP1 polymorphism increases the risk for gestational 
diabetes mellitus. Gynecol Endocrinol. 2015; 31(1): 83–86, doi: 
10.3109/09513590.2014.958994, indexed in Pubmed: 25222839.
9. Michalak-Wojnowska M, Gorczyca-Siudak D, Gorczyca T, et al. Association 
between rs7901695 and rs7903146 polymorphisms of the TCF7L2 gene and 
gestational diabetes in the population of Southern Poland. Ginekol Pol. 2016; 
87(11): 745–750, doi: 10.5603/GP.2016.0081, indexed in Pubmed: 27958632.
10. Tarnowski M, Wieczorek A, Dziedziejko V, et al. IL16 and IL18 gene poly-
morphisms in women with gestational diabetes. Ginekol Pol. 2017; 88(5): 
249–254, doi: 10.5603/GP.a2017.0047, indexed in Pubmed: 28580570.
11. Widén E, Lehto M, Kanninen T, et al. Association of a polymorphism 
in the beta 3-adrenergic-receptor gene with features of the insulin 
resistance syndrome in Finns. N Engl J Med. 1995; 333(6): 348–351, 
doi: 10.1056/NEJM199508103330604, indexed in Pubmed: 7609751.
12. Bhatti JS, Bhatti GK, Mastana SS, et al. ENPP1/PC-1 K121Q polymorphism 
and genetic susceptibility to type 2 diabetes in North Indians. Mol Cell 
Biochem. 2010; 345(1-2): 249–257, doi: 10.1007/s11010-010-0579-2, 
indexed in Pubmed: 20820885.
13. Hod M, Kapur A, Sacks DA, et al. The International Federation of 
Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes 
mellitus: A pragmatic guide for diagnosis, management, and care. Int 
J Gynaecol Obstet. 2015; 131 Suppl 3: S173–S211, doi: 10.1016/S0020-
7292(15)30033-3, indexed in Pubmed: 29644654.
14. Wender-Ożegowska E, Bomba-Opoń D, Brązert J, et al. Standards of 
Polish Society of Gynecologists and Obstetricians in management 
of women with diabetes. Ginekol Pol. 2018; 89(6): 341–350, doi: 
10.5603/GP.a2018.0059, indexed in Pubmed: 30010185.
15. Lambrinoudaki I, Vlachou SA, Creatsas G. Genetics in gestational diabetes 
mellitus: association with incidence, severity, pregnancy outcome and 
response to treatment. Curr Diabetes Rev. 2010; 6(6): 393–399, indexed 
in Pubmed: 20879971.
16. Tok EC, Ertunc D, Bilgin O, et al. Association of insulin receptor substrate-1 
G972R variant with baseline characteristics of the patients with gesta-
tional diabetes mellitus. Am J Obstet Gynecol. 2006; 194(3): 868–872, 
doi: 10.1016/j.ajog.2005.08.067, indexed in Pubmed: 16522427.
17. Schmitz-Peiffer C, Whitehead JP. IRS-1 regulation in health and disease. 
IUBMB Life. 2003; 55(7): 367–374, doi: 10.1080/1521654031000138569, 
indexed in Pubmed: 14584587.
18. Bacci S, De Cosmo S, Prudente S, et al. ENPP1 gene, insulin resistance and 
related clinical outcomes. Curr Opin Clin Nutr Metab Care. 2007; 10(4): 403–
409, doi: 10.1097/MCO.0b013e3281e386c9, indexed in Pubmed: 17563456.
19. Abate N, Chandalia M, Di Paola R, et al. Mechanisms of disease: Ecto-
nucleotide pyrophosphatase phosphodiesterase 1 as a ‚gatekeeper’ of 
insulin receptors. Nat Clin Pract Endocrinol Metab. 2006; 2(12): 694–701, 
doi: 10.1038/ncpendmet0367, indexed in Pubmed: 17143316.
20. Kautzky-Willer A, Harreiter J, Pacini G. Sex and Gender Differences in Risk, 
Pathophysiology and Complications of Type 2 Diabetes Mellitus. En-
docr Rev. 2016; 37(3): 278–316, doi: 10.1210/er.2015-1137, indexed in 
Pubmed: 27159875.
21. Wakabayashi I. Age-dependent influence of gender on the association 
between obesity and a cluster of cardiometabolic risk factors. Gend 
Med. 2012; 9(4): 267–277, doi: 10.1016/j.genm.2012.05.004, indexed 
in Pubmed: 22748425.
22. Chen J, Meng Y, Zhou J, et al. Identifying Candidate Genes for Type 2 
Diabetes Mellitus and Obesity through Gene Expression Profiling in 
Multiple Tissues or Cells. Journal of Diabetes Research. 2013; 2013: 1–9, 
doi: 10.1155/2013/970435.
